Compare AbCellera Biologics Inc (ABCL) vs Entegris Inc (ENTG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Entegris Inc — how do they compare? AbCellera Biologics Inc trades at $7.2 (market cap $2.35B), while Entegris Inc trades at $140.95 (market cap $20.57B). The key difference: Entegris Inc is far larger — about 8.8× AbCellera Biologics Inc's market cap, and Entegris Inc pays a 0.3% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ENTG | |
|---|---|---|
Market Cap | $2.35B | $20.57B |
Sector | Health | Technology |
52-Week High | $8.12 | $184.00 |
52-Week Low | $2.78 | $68.80 |
Enterprise Value | $1.99B | $23.89B |
Dividend Yield | — | 0.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
ENTG is trading at $135.08, down 7.9% today, with a bearish technical signal and neutral oscillators. The company reported strong Q1 2026 earnings of $0.86 per share, beating estimates, and maintains solid fundamentals with $3.2B revenue and 8.18% net income margin. Recent developments include a strategic cross-licensing agreement for EUV lithography and appointment of a new CFO.
Wall Street maintains a bullish outlook with 65% buy ratings and $178.40 consensus price target, representing 32% upside potential. Key risks include premium valuation (P/E 83.91), semiconductor cycle sensitivity, and execution challenges. The stock offers growth exposure to AI-driven semiconductor demand but requires careful monitoring of quarterly execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
